1. Scrip

AstraZeneca's 13 Outcomes-Based Contracts Show “Proactive" Engagement On New Models

 
• By Jessica Merrill

AstraZeneca VP-Market Access Rick Suarez talks about challenges and opportunities in the emerging area of innovative outcomes-based reimbursement contracts, and specifically two new contracts with Harvard Pilgrim for Bydureon and Brilinta.

Handshake of businessmen

AstraZeneca PLC has signed two new outcomes-based reimbursement contracts with Harvard Pilgrim Health Care for the blood thinner Brilinta (tocagrelor) and the diabetes drug Bydureon (exenatide extended release), bringing the total number of the company's value-based reimbursement contracts to 13.

The double-digit number represents a significant amount of contracts in what is an exploratory area for the industry, as pharma manufacturers and insurers

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.